Quantcast
Last updated on April 17, 2014 at 12:58 EDT

Latest Eisai Co. Ltd. Stories

2008-12-02 08:00:00

Randomized Comparator Study to Evaluate Efficacy of Commercially Available Hypomethylating Agents WOODCLIFF LAKE, N.J., Dec. 2 /PRNewswire/ -- Eisai Corporation of North America today announced that it plans to initiate the first clinical trial evaluating the activity of Dacogen(R) (decitabine for injection) compared to Vidaza(R) (azacitidine) in adult patients with intermediate-1, intermediate-2 or high-risk myelodysplastic syndromes (MDS), a potentially life-threatening group of bone...

2008-10-16 00:00:05

WOODCLIFF LAKE, N.J., Oct. 15 /PRNewswire/ -- Eisai Corporation of North America announced today that the U.S. Food and Drug Administration (FDA) has approved an efficacy supplemental biologics license application (sBLA) for ONTAK(R) (denileukin diftitox) solution for intravenous injection for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the interleukin (IL)-2 receptor (CD25+). A separate efficacy...

2008-09-25 09:00:54

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, and Pivotal BioSciences, Inc., a privately held Los Angeles-based biotechnology company developing oncology products, today announced they have entered into an agreement in which Morphotek will access Pivotal BioSciences' LEC platform technology, developed by Dr. Alan Epstein, M.D., Ph.D, for the development of therapeutic monoclonal antibodies. The technology enhances the human immune system's ability to produce an...

2008-09-15 09:00:58

Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue. http://www.reportlinker.com/p092000/The-World-Alzheimers-Disease-Market-(Incidence-Treatments-Key-Companies-Pipeline-and-Trends).html Alzheimer's Disease is the most common cause of dementia, constituting 60% to 70% of all cases, and the risk with the disease doubles every 5 years after age 65. Incidence of the disease is increasing, and the resulting...

2008-08-26 09:00:28

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced that it has opened clinical sites in the European Union (EU) as part of the company's MORAb-009 Phase II study. The study is evaluating MORAb-009, a monoclonal antibody to mesothelin, as a first-line treatment for patients with pancreatic cancer. The randomized, controlled, double-blinded trial will compare MORAb-009 plus gemcitabine with a placebo plus gemcitabine. Morphotek has currently qualified...

2008-08-23 12:00:22

WOODCLIFF LAKE, N.J., Aug. 23 /PRNewswire/ -- Eisai Corporation of North America and its partner Helsinn Healthcare SA today announced that the U.S. Food and Drug Administration (FDA) has approved a new oral formulation of ALOXI(R) (palonosetron hydrochloride) for the prevention of chemotherapy-induced nausea and vomiting (CINV). ALOXI Capsules 0.5 mg for oral administration is indicated for the prevention of acute nausea and vomiting following initial and repeat courses of moderately...

2008-08-13 09:00:13

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that it has signed a license agreement with the National Cancer Institute (NCI) for the rights to a monoclonal antibody for a novel antigen identified by NCI researchers. Morphotek will apply its proprietary MORPHODOMA(R) antibody technology to the development of novel human therapeutic antibodies for use in the treatment of prostate cancer. "This agreement represents another important milestone in our...

2008-07-25 18:00:57

WOODCLIFF LAKE, N.J., July 25 /PRNewswire/ -- Eisai Corporation of North America today announced that it has received a not approvable letter from the U.S. Food and Drug Administration (FDA), which outlines a pathway to potential approval of fospropofol disodium for use by appropriately trained physicians. Fospropofol disodium injection has been in review at the FDA for use as an intravenous sedative-hypnotic agent for sedation in adult patients undergoing diagnostic or therapeutic...

2008-07-24 09:01:13

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced that Rodney Dausch, Vice President and Chief Financial Officer (CFO), received the Philadelphia Business Journal/Drexel University's LeBow College of Business Small Company CFO of the Year Award. According to the Journal, the award recognizes outstanding CFOs who strategically lead their company's growth, profits and marketing position in addition to maintain its reputation, ethics and accountability to...

2008-07-21 18:00:46

TOKYO and WOODCLIFF LAKE, N.J., July 21 /PRNewswire/ -- With respect to Eisai's patent infringement lawsuit against Teva Pharmaceuticals and Dr. Reddy's Laboratories concerning Aciphex(R) (generic name: rabeprazole sodium tablets, Product Name in Japan: Pariet(R)), Eisai Co., Ltd. and its U.S. subsidiary Eisai Inc. (collectively "Eisai") today announce that the United States Court of Appeals for the Federal Circuit has affirmed both the United States District Court for the Southern District...